Aytu BioPharma, Inc. (AYTU) key performance indicators and operating metrics (5 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Adjusted Earnings Before Interest Taxes Depreciation and Amortization | -800K | FY2026-Q2 |
| Attention Deficit Hyperactivity Disorder Portfolio Net Revenue | 13.22M | FY2026-Q2 |
| Pediatric Portfolio Net Revenue | 1.69M | FY2026-Q2 |
| Net Revenue from Other | 19K | FY2026-Q2 |
| Attention Deficit Hyperactivity Disorder Prescriptions Written (Approximate) | 99K | FY2025-Q2 |
Back to AYTU overview · AYTU earnings · AYTU holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.